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CD44The cluster determinant (CD44) seems to play a key role in tissues injured by diabetes type 2. CD44
stimulation activates the protein kinase C (PKC) family which in turn activates the transcriptional nuclear
factor kappa B (NF-κB) responsible for the expression of the inﬂammation mediators such as tumor necrosis
factor alpha (TNF-α), interleukin-6 (IL-6), interleukin-18 (IL-18), inducible nitric oxide synthase (iNOS), and
matrix metalloproteinases (MMPs). Regulation of CD44 interaction with its ligands depends greatly upon
PKC. We investigated the effect of the treatment with high-molecular weight hyaluronan (HA) on diabetic
nephropathy in genetically diabetic mice.
BKS.Cg-m+/+Leprdb mice had elevated plasma insulin from 15 days of age and high blood sugar levels at
4 weeks. The severe nephropathy that developed was characterized by a marked increased in CD44
receptors, protein kinase C betaI, betaII, and epsilon (PKCβI, PKCβII, and PKCε) mRNA expression and the
related protein products in kidney tissue. High levels of mRNA and related protein levels were also detected
in the damaged kidney for NF-κB, TNF-α, IL-6, IL-18, MMP-7, and iNOS.
Chronic daily administration of high-molecular mass HA for 2 weeks signiﬁcantly reduced CD44, PKCβI,
PKCβII, and PKCα gene expression and the related protein production in kidney tissue and TNF-α, IL-6, IL-18,
MMP-7, and iNOS expression and levels also decreased. Histological analysis conﬁrmed the biochemical data.
However, blood parameters of diabetes were unchanged.
These results suggest that the CD44 and PKC play an important role in diabetes and interaction of high-
molecular weight HA with these proteins may reduce inﬂammation and secondary pathologies due to this
disease., Physiological and Nutritional
oliclinico Universitario, Torre
Italy. Tel.: +39 90 221 3334;
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Over the last decade, considerable evidence has demonstrated the
molecular and cellular links between metabolism and inﬂammation,
particularly in obesity and diabetes. Diabetic nephropathy is one of
the major microvascular complications in diabetes, and it is the most
common single cause of end-stage renal disease worldwide [1]. The
development of diabetic nephropathy is described as a process
progressing from moderate glomerular hyperﬁltration and nephro-megaly to frank proteinuria with severe hypertension and marked
renal insufﬁciency until end-stage renal disease [2]. Chronic inﬂam-
mation, characterized by elevated circulating levels of inﬂammatory
markers, appears to play a critical role in the pathogenesis of type 2
diabetes and its associated complications, particularly diabetic
nephropathy and the consequent cardiovascular risk [3]. Recent
evidence indicates that chemokines, interleukins, adhesionmolecules,
growth factors, and free radicals are deeply involved in the
development of diabetic nephropathy [4,5]. The cytokines that seem
to play a key role in diabetic renal failure include proinﬂammatory
cytokines such as tumor necrosis alpha (TNF-α), interleukin-6 (IL-6),
and interleukin-18 (IL-18) [6–8]. Inducible nitric oxide synthase
(iNOS) and cytokine-stimulated metalloproteinases (MMPs), espe-
cially MMP-7, are also greatly involved in the development of diabetic
complications and kidney damage [9,10]. One ROS, nitric oxide (NO),
1119G.M. Campo et al. / Biochimica et Biophysica Acta 1802 (2010) 1118–1130is a highly reactive, cytotoxic molecule that is heavily implicated in
diabetes [11]. Increased levels of NO promote numerous effects on
podocytes, including alteration of the extracellular matrix synthesis
[12] and activation of apoptosis [13].
Biologics that inhibit the signalling cascade mediated by proinﬂam-
matory cytokinesare effective in treatingdiabeticpathologiesby reducing
both inﬂammation and renal failure [6,14,15]. However, blocking IL-18
and/or TNF-α does not lead to total protection from diabetic complica-
tions, indicating that other signalling pathways that mediate inﬂamma-
tion and tissue injury have still to be elucidated [6,14,15].
Hyaluronan (HA) is a linear polymer composed of repeating
disaccharides of D-glucuronic acid–N-acetyl D-glucosamine [16]. HA can
exist as a high-molecular-weight polymer (106 D) or in lower-molecular
weight forms. Low-molecular mass HA in particular is produced after
tissue injury [17]. Several ﬁndings have shown that HA functions are
determined in part by the size of the molecule. High-molecular weight
HA is suggested to play a structural role and to promote tissue integrity,
while low-molecular weight HAmay be a signal of tissue injury [18–20].
The best-known HA receptor is CD44 [21]; it is a transmembrane
glycoprotein which is widely found in T lymphocytes, granulocytes,
monocytes, ﬁbroblasts, keratinocytes, and epithelial cells. CD44
stimulation with HA plays a role in various physiological functions,
such as cell adhesion, cell–substrate interactions, and lymphocyte
recruitment, as well as in pathological processes such as chronic
inﬂammation and metastasis of malignant cells [22]. A role for CD44,
as HA receptor, in the regulation of inﬂammation in vivo has been
shown by studies in which anti-CD44 treatment reduces not only
inﬂammation in experimental diabetes [23,24] but also leukocyte
migration in skin-associated immune disease [25].
A number of reports have shown PKC members to be greatly
involved in the mediation of inﬂammation [26]. The regulation of
CD44 interaction with its ligands depends heavily on PKC which
modulates the phosphorylation state of CD44 [27] and the various
anchoring proteins [28]. Interestingly, PKC activation leads to the
redistribution of CD44 receptors in membrane rufﬂes located at the
leading edge of glioma cells [29]; a key feature of inﬂammation and
invading cells. PKC therefore has the potential to modulate both the
afﬁnity of CD44 for HA [30] as well as the localization of the receptor
over the cell surface [29]. It has also been reported that the activation
of the CD44 receptor by HA produces PKC activation [31], thus
establishing a concatenated mechanism between the CD44 receptor
and PKC. In addition, these processes are to a large extent mediated by
the increased expression of proinﬂammatory cytokines and other
detrimental molecules such as NO and MMPs, which are in turn
controlled by the activation of key transcriptional nuclear factor kappa
B (NF-κB) [32].
As previous investigations reported that the inhibition of PKC
isoforms such as PKCα, PKCβI and PKCβII reduces diabetic complica-
tions, especially diabetic nephropathy [33–35], and since we
demonstrated in a previous study that high-molecular mass HA is
able to reduce phorbol-12-myristate-13-acetate (PMA)-induced
inﬂammation in mouse chondrocytes by interacting with PKC [19],
the aim of this study was to investigate whether high-molecular
weight HA administration, at different concentrations, inﬂuences
CD44 and PKC function in congenic diabetic BKS.Cg-m+/+Leprdb
mice.
2. Materials and methods
2.1. Animals
Male congenic diabetic BKS.Cg-m+/+Leprdb mice 15 weeks old
with ameanweight of 25–30 gwere used in our study.Mice, purchased
from The Jackson Laboratory (Bar Harbor, ME, USA) were maintained
under climate-controlled conditions with a 12-h light/dark cycle. The
animals were fed standard rodent chow and provided water ad libitum.The health status of the animal colony was monitored in accordance
with Italian Veterinary Board guidelines. Mice were divided into the
following groups: 1) control (n=12), 2) control+HA (30 mg/kg)
(n=12), 3) diabetic (n=17), 4) diabetic+HA (7.5 mg/kg) (n=17), 5)
diabetic+HA (15 mg/kg) (n=17), 6) diabetic+HA (30 mg/kg)
(n=17).
2.2. Materials
High molecular weight HA (4,000,000 Da) was purchased from
Sigma-Aldrich Srl, (Milan, Italy). Mouse TNF-α (cat. IB49688), IL-6
(cat. IB49686), IL-18 (cat. IB49697) commercial ELISA kits were
provided by Immuno-Biological laboratories Inc. (Minneapolis, MN,
USA). Mouse MMP-7 (cat. E0102Mu) and iNOS (cat. E0837Mu)
commercial ELISA kits were obtained from USCN Life Science Inc.
Wuhan (Wuhan, China). Mouse CD44 monoclonal antibodies were
supplied by Millipore (Billerica, MA, USA), mouse PKCα monoclonal
antibodies were supplied by Abcam plc (Cambridge, UK), mouse
PKCβII polyclonal antibodies were supplied by Sigma-Aldrich (Milan,
Italy), and PKCβI polyclonal antibodies and horseradish peroxidase-
labeled goat anti-rabbit antibodies were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). All other reagents used were
purchased from Fluka (division of Sigma-Aldrich Srl, Milan, Italy).
2.3. HA treatment
HA was dissolved in saline solution (0.9% NaCl) at three different
concentrations (7.5, 15, and 30 mg/kg) and administered intraper-
itoneally at a volume of 1.0 ml/kg body weight, once a day starting
from day 1 up to day 15.
2.4. Plasma glucose and insulin
Glucosewas evaluated in plasma samples (100 μl) at the end of the
experiment. Concentrations were assayed using commercial clinical
test kits (cat. GAGO20) obtained from Sigma-Aldrich (Milan, Italy).
Insulin levels were alsomeasured in plasma samples (10 μl) at the end
of the experiment using an ELISA commercial kit (cat. EZRMI-13 K)
provided by Millipore (Billerica, MA, USA).
2.5. RNA isolation, cDNA synthesis, and real-time quantitative PCR
ampliﬁcation
Total RNA was isolated from renal tissue for reverse-PCR real-time
analysis of CD44, PKCβI, PKCβII, PKCα, TNF-α, IL-6, IL-18, MMP-7, and
iNOS (RealTime PCR system, Mod. 7500; Applied Biosystems, USA)
using an Omnizol Reagent Kit (Euroclone, West York, UK). The ﬁrst
strand of cDNA was synthesized from 1.0 μg total RNA using a high-
capacity cDNA Archive kit (Applied Biosystems, USA). β-Actin mRNA
was used as an endogenous control to allow the relative quantiﬁcation
of. CD44, PKCβI, PKCβII, PKCα, TNF-α, IL-6, IL-18,MMP-7, and iNOS. Real-
time PCR was performed by means of ready-to-use assays (Assays on
demand;Applied Biosystems) on both targets and endogenous controls.
The ampliﬁed PCR products were quantiﬁed by measuring the
calculated cycle thresholds (CT) of CD44, PKCβI, PKCβII, PKCα , TNF-α,
IL-6, IL-18, MMP-7, iNOS, and β-actin mRNA. The amounts of speciﬁc
mRNA in samples were calculated using the ΔΔCT method. The mean
value of normal cartilage target levels became the calibrator (one per
sample), and the results are expressedas then-fold difference relative to
normal controls (relative expression levels).
2.6. Western blot assay of CD44, PKCβI, PKCβII, and PKCα proteins
For SDS–PAGE and Western blotting, the kidney tissue samples
were washed twice in ice-cold PBS and subsequently dissolved in SDS
sample buffer (62.5 mM Tris–HCl, pH 6.8, 2% wt./vol. SDS, 10%
1120 G.M. Campo et al. / Biochimica et Biophysica Acta 1802 (2010) 1118–1130glycerol, 50 mM dithiothreitol, 0.01% wt./vol. bromophenol blue).
Aliquots of whole cell protein extract (10–25 μl/well) were separated
on a mini gel (10%). The proteins were blotted onto polyvinylidene
diﬂuoride membranes (Amersham Biosciences) using a semidry
apparatus (Bio-Rad). The membranes were then incubated overnight
in a roller bottle with the speciﬁc diluted (1:1000) primary antibody
in 5% bovine serum albumin, 1x PBS, and 0.1% Tween 20 at 4 °C. After
being washed in three stages in wash buffer (1x PBS, 0.1% Tween 20),
the blots were incubated with the diluted (1:2500) secondary
polyclonal antibody (goat anti-rabbit conjugated with peroxidase),
in TBS/Tween-20 buffer, containing 5% nonfat dried milk. After
45 min of gentle shaking, the blots were washed ﬁve times in wash
buffer, and the proteins, after coloration with DAB liquid substrate
(Sigma-Aldrich, Milan, Italy) were made visible using a UV/visible
transilluminator (EuroClone, Milan, Italy) and Kodak BioMax MR
ﬁlms. A densitometric analysis was also run to quantify each band.4
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Fig. 1. Effect of HA treatment on CD44 mRNA expression (A) and related protein production
and are expressed as the n-fold increase with respect to the control (A) and as both densito
control; *pb0.01, **pb0.005, and ***pb0.001 vs diabetic.2.7. NF-κB p50/65 transcription factor assay
NF-κBp50/65DNAbinding activity innuclear extracts of kidney tissue
sampleswasevaluated inorder tomeasure thedegreeofNF-κBactivation.
Analysis was performed in line with the manufacturer's protocol for a
commercial kit (NF-κB p50/65 Transcription Factor Assay Colorimetric,
cat. no. SGT510; Chemicon International, USA). In brief, one of the kidneys
was removed from the animals at the end of the experimental phase,
washed in ice-cold 10 mM Tris–HCl, pH 7.4, and blotted on an absorbent
paper. Samples were then plotted, using an automatic plotter, to isolate
renal cells. Cytosolic and nuclear extraction was performed by lysing the
cell membrane with an appropriate hypotonic lysis buffer containing
protease inhibitor cocktail and tributylphosphine (TBP) as reducing agent.
After centrifugation at 8000 ×g, the supernatant containing the cytosolic
fraction was discarded, while the pellet containing the nuclear portion
was then resuspended in the apposite extraction buffer, and the nuclei*
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(B, C) in kidney tissue of diabetic mice. Values are the mean±SD of seven experiments
metric analysis (C) and Western blot analysis (B) for CD44 protein levels. °pb0.001 vs
1121G.M. Campo et al. / Biochimica et Biophysica Acta 1802 (2010) 1118–1130were disrupted by a series of drawing and ejecting actions. The nuclear
suspension was then centrifuged at 16,000×g. The supernatant fraction
was the nuclear extract. After determination of protein concentration and
adjustment to a ﬁnal concentration of approximately 4.0 mg/ml, this
extract was stored in aliquots at−80 °C for the subsequent NF-κB assay.
After incubation with primary and secondary antibodies, colour devel-
opment was observed following the addition of the substrate TMB/E.
Finally, the absorbance of the samples was measured using a spectro-
photometric microplate reader set at λ 450 nm. Values are expressed as
relative optical density (OD) per mg protein.
2.8. TNF-α, IL-6, IL-18, MMP-7, and iNOS ELISA assay
Tissue samples obtained from mice kidneys in the presence of
1.0 nM PMSF and protease inhibitor cocktail were ﬁrst lysed using a5
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Fig. 2. Effect of HA treatment on PKCβI mRNA expression (A) and related protein production
and are expressed as the n-fold increase with respect to the control (A) and as both densito
control; *pb0.01, **pb0.005, and ***pb0.001 vs diabetic.suitable hypotonic lysis buffer and then centrifuged at 13,000 rpm for
10 min at 4 °C. The analysis of TNF-α, IL-6, and IL-18 was carried out
using a speciﬁc commercial kit. Brieﬂy, 50 μl of standards, samples, and
controlswere added to eachwell of the coatedmicroplate. Then, 50 μl of
each speciﬁc biotin-conjugate antibody was then added to each well.
After 120 min of incubation at 20–22 °C, the liquid from the wells was
discarded, the wells were washed three times and 100 μl of Streptavi-
din–HRP was added. After further incubation for 60 min and having
washed the wells once more, 100 μl of a substrate chromogen solution
was added. After 10 min of incubation and the addition of 100 μl of stop
solution, the absorbance of each well was read spectrophotometrically
at λ 450 nm. TNF-α, IL-6, and IL-18 values are expressed as picograms
per milligram of protein. For MMP-7 and iNOS, 100 μl of previously
diluted samples, standards, and controls were added to eachwell of the
coated microplate. After incubation for 2 hours at 37 °C, the liquid from*
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(B, C) in kidney tissue of diabetic mice. Values are the mean±SD of seven experiments
metric analysis (C) and Western blot analysis (B) for PKCβI protein levels. °pb0.001 vs
1122 G.M. Campo et al. / Biochimica et Biophysica Acta 1802 (2010) 1118–1130each well was discarded. After adding 100 μl of the detection reagent A
and incubation at 37 °C for 1 hour, the liquid was aspirated, and wells
were washed with wash buffer. At this point, 100 ml of detection
reagent B was added to each well, and after a further incubation for
1 hour at 37 °C, the liquid of wells was ﬁrst aspirated then wells were
washed with wash buffer. Then, 90 μl of the substrate solution was
added, and after incubation at room temperature for 30minutes, 50 μl of
stop solution was added. Within 30 minutes, the absorbance of each
well was read spectrophotometrically at λ 450 nm. MMP-7 values are
expressed as picograms per milligram of protein, while iNOS values are
expressed as units per milligram of protein.
2.9. Histology
At theendof theexperimental phase, the rightkidneywasﬁrst excised
and then perfused with 4% paraformaldeyde (PFA)/0.1 M phosphate
buffer (PB), decapsulated, and immersed in 4% PFA/0.1 M PB. Then4
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Fig. 3. Effect of HA treatment on PKCβII mRNA expression (A) and related protein production
and are expressed as the n-fold increase with respect to the control (A) and as both densito
control; *pb0.01, **pb0.005, and ***pb0.001 vs diabetic.kidneys were dehydrated in graded ethanol and embedded in a special
tissue embeddingmedia (Paraplast, McCormick Scientiﬁc, Richmond, VA,
USA). Sections of 4 μm thickness were cut with a microtome (mod. RM
2125 RT; Leica Camera AG, Solms, Germany), stained with hematoxylin–
eosin technique and viewed and photographed with a light microscope
(mod. BH2; Olympus America Inc., Melville, USA).
2.10. Protein analysis
The amount of protein was determined using the Bio-Rad protein
assay system (Bio-Rad Lab., Richmond, CA, USA) with bovine serum
albumin as a standard in accordance with the published method [36].
2.11. Statistical analysis
Data are expressed asmeans±SDof no less than seven experiments
for each test. Statistical analysis was performed by one-way analysis of*
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(B, C) in kidney tissue of diabetic mice. Values are the mean±SD of seven experiments
metric analysis (C) and Western blot analysis (B) for PKCβII protein levels. °pb0.001 vs
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statistical signiﬁcance of differences was set at pb0.05.
2.12. Statement of animal care
The studies reported in this article were carried out in accordance
with the Helsinki declaration and the NIH guidelines for the Care and
Use of Laboratory Animals.
3. Results
3.1. Effects of HA treatment on plasma glucose and insulin
At the age of 4 weeks, the acute expression of the db/db mutation
commonly induces noticeable alterations in body phenotype, tissue4
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Fig. 4. Effect of HA treatment on PKCα mRNA expression (A) and related protein production
and are expressed as the n-fold increase with respect to the control (A) and as both densito
control; *pb0.01, **pb0.005, and ***pb0.001 vs diabetic.indexes, and the endocrine-related parameters of BKS.Cg-m+/+Leprdb
mice relative to controls [37]. Increased body weight in these mice is
related to concomitant elevations in blood glucose and insulin levels
when compared with control values [37]. The 15-day HA treatment
period, at all doses, had no effect on plasma glucose and insulin in both
diabetic and control mice (data not shown).
3.2. CD44, PKCβI, PKCβII, and PKCα mRNA expression and Western blot
analysis
CD44, PKCβI, PKCβII, and PKCα (Figs. 1, 2, 3, and 4) mRNA
evaluation (panels A of each ﬁgure) and Western blot analysis with
densitometric evaluation (Figs. 1, 2, 3, and 4, panels B and C of each
ﬁgure) were assayed to estimate the degree of CD44 activation and
the consequent cell signalling pathway booster that culminates in NF-*
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(B, C) in kidney tissue of diabetic mice. Values are the mean±SD of seven experiments
metric analysis (C) and Western blot analysis (B) for PKCα protein levels. °pb0.001 vs
1124 G.M. Campo et al. / Biochimica et Biophysica Acta 1802 (2010) 1118–1130κB factor activation. Very low gene expression and the related protein
production of CD44, PKCβI, PKCβII, and PKCα were obtained in
nondiabetic mice (CTRL and CTRL+HA). In contrast, a marked
increase in the expression and protein synthesis of the CD44 receptor
and their signal mediators PKCβI, PKCβII, and PKCα was found in the
kidney tissue of diabetic mice. This means that CD44 receptor and the
PKC pathway are involved in the inﬂammatory mechanism conse-
quent to this pathology.
The treatment with high-molecular weight HA for 15 days
signiﬁcantly reduced CD44 receptor activation and its signal mediator
levels in diabetic mice. As reported in Figs. 1, 2, 3, and 4, HA was able
to lower CD44, PKCβI, PKCβII, and PKCα expression and protein
synthesis at all concentrations in a dose-dependent manner.
3.3. NF-κB activation
Fig. 5 shows the changes in the NF-κB p50/p65 heterodimer
translocation over the course of the experiment. NF-κB DNA binding
was present at very low levels in the renal tissue of nondiabetic mice.
In contrast, diabetic complications induced massive NF-κB transloca-
tion into the nucleus of the damaged podocytes; the treatment of
diabetic mice with HA at different concentrations reduced NF-κB
activation in a dose-dependent manner, thereby conﬁrming the effect
on CD44, PKCβI, PKCβII, and PKCα parameters.
3.4. TNF-α, IL-6, IL-18, MMP-7, and iNOS mRNA expression and ELISA
assay
TNF-α, IL-6, IL-18, MMP-7, and iNOS were assayed because of their
active role in inﬂammation and diabetic nephropathy (Figs. 6, 7, 8, 9,
and 10). Their mRNA evaluation (panel A of each ﬁgure) and protein
concentration (panel B of each ﬁgure) showed that the mRNA of these
detrimental mediators was not stimulated in nondiabetic mice and
protein level was very low. However, in diabetic mice, TNF-α, IL-6, IL-
18, MMP-7, and iNOS expression and the related protein concentra-3
°
°
1,5
N
F-
kB
 a
ct
iv
at
io
n(
OD
45
0n
m
/m
g 
pr
ot
ei
n)
 
0
CTRL DMCTRL +HA
30 mg/kg
Fig. 5. Effect of HA treatment on NF-κB p50/65 transcription factor DNA binding activity in ki
the p/65 subunit. Values are the mean±SD of seven experiments and are expressed as optica
**pb0.001 vs diabetic.tion were signiﬁcantly upregulated. The administration of high-
molecular weight HA was able to reduce this increment in mRNA
expression at all doses. As reported (Figs. 6, 7, 8, 9, and 10; panels A
and B of each ﬁgure), the increase in mRNA expression of TNF-α, IL-6,
IL-18, MMP-7 and iNOS in diabetic mice correlated well with the
increment in protein synthesis. This correlation was also maintained
in mice treated with HA. In fact, the reduction in mRNA expression
resulted in a similar diminution in protein formation.
3.5. Histological analysis
Glomerular injury in the diabetic mice can be early characterized
by glomerular hyperplasia and mesangial matrix expansion. Fig. 11
demonstrates a representative kidney histopathology of all the
experimental groups. Panels A and B show a normal kidney tissue
section from nondiabetic control mice untreated or treated with HA.
In contrast, as reported in Fig. 11, panel C, the glomerular hyperplasia
and mainly the mesangial cell increment is clearly evident. In panels
D, E, and F, a representative selection of kidney tissue sections from
diabetic mice receiving HA treatment shows that a gradual reduction
in glomerular hyperplasia and mesangial matrix expansion occurred.
As indicated by the intensive coloration, the number of mesangial
cells increased dramatically.
4. Discussion
Diabetes is a chronic disease in which patients develop dramatic
and devastating complications. The most severe complication of
diabetes is nephropathy, which frequently causes death in diabetic
patients and accounts for a large number of cases of end-stage renal
disease.
In the present study, we investigated the effects of high-molecular
weight HA, at different concentrations, on CD44 receptor modulation
in congenitally diabetic mice. This study suggests that highly
polymerized HA may reduce diabetes-induced renal injury by*
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HA which may exert the opposite effects as previously demonstrated
[17–20]. HA effects were dose dependent and were able to reduce not
only the expression of CD44 receptor and of PKCβI, PKCβII, and PKCα
but also NF-κB activation and the increment of inﬂammatory
cytokines, such as IL-6 and IL-18, and of MMP-7 and iNOS that were
upregulated in diabetic mice. Biochemical results were further
conﬁrmed by the reduction in glomerulosclerosis as revealed by the
histological analysis.
HA possesses an extraordinarily rapid half-life. It is quickly
eliminated by means of CD44 receptors on liver endothelium. At a
normal plasma concentration, the half-life is approximately 4–
6 minutes, while at higher plasma concentrations, the HA half-life is
considerable prolonged to 18–43 minutes [38]. The intraperitoneal
HA half-life is unknown but is probably also very rapid, and also in this
case, an increase in the HA dose administered may result in a
prolonged HA half-life with a consequent major bioavailability to
different organs. Therefore, we might expect a linear progression of
effect by increasing the HA range concentrations administered.
However, due to its viscous properties, it is really difﬁcult to
administer concentrations higher than 30 mg/kg.
The interaction between cell surface CD44 and extracellular HA are
implicated in a variety of physiological and pathological processes,
such as the uptake and degradation of HA, T-cell activation, leukocyte
extravasation at inﬂammation sites, and tumor metastasis [39]. CD44expression in the renal tissue correlates with the degree of the
nephropathy in diabetic rats [40] and at high levels in several other
form of nephropathy stimulates the increment in inﬂammatory
mediators that are the main cause of renal damage [41,42].
Protein kinaseC (PKC) is a family of phospholipid-dependent serine/
threonine kinases that consists of a number of isoforms [43]. The
differences between the PKC isoforms dependent on their substrate
speciﬁcity suggest that a particular PKC isoformwithin a single cell may
regulate speciﬁc physiological responses. PKCs regulate a variety of
biological functions including ion channel activity, cell differentiation,
and other biochemical and physiological responses to various stimuli
[44,45]. The PKC/PKD family exerts numerous effects on cellular
pathways that are important in inﬂammation and has previously been
considered as a potential therapeutic target in diabetes [33–35,46]. PKC
is able tomodify the phosphorylation state of the CD44 receptor and the
interaction with HA [27], and PKC in turn may be activated through
different pathways, among these by CD44 stimulation [31]. Therefore,
CD44 and PKC are interdependent and greatly involved in the
inﬂammation cascade. NF-κB promotes the transcription of several
genes including cytokines and other inﬂammation products [32]. CD44
stimulation activates members of the PKC family, such as PKCα and
PKCβ [47,48], which in turn activate the NF-κB responsible for the
expression of inﬂammation mediators such as TNF-α, IL-6, IL-18, iNOS,
its dangerous free radical product, NO, and MMPs responsible for
diabetic nephropathy [5–13,49–51].
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fundamental in many physiological and pathological mechanisms.
Proteoglycans (PGs) may inﬂuence cell behaviour through binding
events mediated by their glycosaminoglycan (GAG) chains. The
binding afﬁnity of the interaction depends on the ability of the
oligosaccharide sequence to provide an optimal charge and surface
with the protein [52]. The interaction of HA degradation products
with CD44 provides signals to initiate inﬂammation [22,23,25]. Other
data support the idea that a balance between low-molecular weight
HA and high-molecular weight HA may control the activation of
inﬂammation [53]. In fact, these preliminary ﬁndings suggest that
high-molecular weight HA is inactive for CD44 modulation, while
low-molecular weight HA originating from depolymerised HA at the
inﬂammation site is active. [17,18,54]. We previously reported that
high-molecular weight HA is able to reduce inﬂammation stimulated
by PMA in mouse chondrocytes. By using a speciﬁc CD44-blocking
antibody, it was demonstrated that PKC and not CD44 receptor is the
target for HA action [19]. We suggest the same mechanism to explain
the ﬁndings of the present study, in which chronic daily administra-
tion of high-molecular mass HA for 2 weeks signiﬁcantly reduced
CD44, PKCβI, PKCβII, and PKCα gene expression and the related protein
production in kidney tissue and TNF-α, IL-6, IL-18, MMP-7, and iNOS
expression levels.
The effect exerted by HA on the parameters considered could be
due to the ability of HA to bind protein structures, such as PKC,thereby exerting a block that reduced NF-κB activation. A similar
effect exerted directly on the CD44 receptor should be excluded, since
the high-molecular mass HA interaction with CD44 seems to be just
one step in a pathway of intermediary metabolism involving the
catabolism of native HA into small fragments [55]. The rationale for
the use of high-molecular mass HA in place of a speciﬁc antibody
targeted at CD44may be explained by the fact that a block of the CD44
receptor leads to the abrogation of several fundamental CD44
functions, such as cell adhesion, cell–substrate interaction, and
lymphocyte recruitment [39].
Blocking PKC isoforms using speciﬁc agents was also previously
attempted, but the effects are not very encouraging because of the
high toxicity of these agents [56]. The choice of HA as a modulating
agent was derived essentially from its natural endogenous origin. The
number of active charged HA sites (carboxylic groups) is responsible
for HA action. In fact, high molecular weight HA contains many
charged groups that may complete wrap protein structures such as
PKC, thereby preventing its activation. The mechanism could be
similar to a well known lock-and-key model which applies to all the
better-known effector-receptors where the effector is chemically
speciﬁc and a similar molecule with several charged groupsmay block
the receptor. In this work, the larger size of HA molecule was able to
mask the PKC active site completely. The resultant inhibition of PKC
thereby produced a reduction in NF-κB activation that in turn limited
the transcription of the detrimental inﬂammatory intermediates with
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of diabetic nephropathy as the results of this study reported.
However, further studies are needed to fully conﬁrm these
hypotheses.Acknowledgements
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